





## JOIN US ON THURSDAY 1ST OF FEBRUARY 2024 - 8H15



Prof. Dr. Bram Verstockt
UZ Leuven



**Prof. Dr. Erwin Dreesen**KU Leuven



CHAIR

**Prof. Dr. Catherine Reenaers** CHU Liège

## The sense & non-sense of Therapeutic Drug Monitoring with subcutaneous infliximab



LOCATION Conference Room: 'Lijn' - 3rd Floor - Hilton Hotel Antwerp



**AGENDA** 

**7h45** Breakfast served

8h15 Welcome

8h20 Highlights of the latest data of TDM with IFX SC8h30 Integrating TDM with IFX SC in the daily practice

**8h40** Discussion and O&A



## **OBJECTIVES**

Understand	Evaluate	Consider
The correlation between the IFX IV trough and IFX SC serum levels	The relationship between serum IFX SC concentrations and therapeutic/clinical outcomes	The integration of TDM of IFX into clinical practice as a tool to monitor patients and guide decision-making on the optimal dosing strategy
Factors influencing IFX SC serum levels	Cut-off values of serum levels to target clinical or deep remission	the optimal assuing strategy

TDM, Therapeutic Drug Monitoring; IFX, infliximab; IV, intravenous; SC, subcutaneous, ©Celltrion Healthcare BeLux, Ikaroslaan 1, 1930 Zaventem BE-REMSC-23-00040 – December 2023



